During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hangzhou TianMuShan Pharmaceutical Enterprise Co was 20.00% per year. The lowest was -22.30% per year. And the median was -1.80% per year.
Back to Basics: PB Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Hangzhou TianMuShan Pharmaceutical Enterprise Co PB Ratio Related Terms
Hangzhou TianMuShan Pharmaceutical Enterprise Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co PB Ratio Chart
Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou TianMuShan Pharmaceutical Enterprise Co PB Ratio vs Drug Manufacturers Industry
Hangzhou TianMuShan Pharmaceutical Enterprise Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) has a PB Ratio of 34.87 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. This is 14% above median its historical median of 30.65. Over the past decade, Hangzhou TianMuShan Pharmaceutical Enterprise Co's PB Ratio has ranged from 7.40 to 81.34. According to the industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #908 out of 925 companies in the Drug Manufacturers industry, placing it in the top 98.2%.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co's PB Ratio too high?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current PB Ratio of 34.87 is 14% above median its 10-year median of 30.65. Over the past 10 years, this metric has ranged from a low of 7.40 to a high of 81.34. The Drug Manufacturers industry median PB Ratio is 1.91. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 34.87 is 1725.7% above this industry median. Based on the distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #908 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hangzhou TianMuShan Pharmaceutical Enterprise Co has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou TianMuShan Pharmaceutical Enterprise Co's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #908 out of 925 companies for PB Ratio. This places Hangzhou TianMuShan Pharmaceutical Enterprise Co in the lower half of its industry. The industry median PB Ratio is 1.91. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 34.87 is 1725.7% above this benchmark. Historically, Hangzhou TianMuShan Pharmaceutical Enterprise Co's own PB Ratio has ranged from 7.40 to 81.34 over the past decade. While the company's 10-year median is 30.65 vs. the industry median of 1.91, Hangzhou TianMuShan Pharmaceutical Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current PB Ratio of 34.87 is 1725.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current PB Ratio is 34.87, which is 14% above median its own 10-year median of 30.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥14.96, compared to a current price of ¥21.13 — trading 41.2% above its estimated fair value. The current PB Ratio is 34.87, which is 14% above median its 10-year median of 30.65 and 1725.7% above the Drug Manufacturers industry median of 1.91. Hangzhou TianMuShan Pharmaceutical Enterprise Co's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671), the current PB Ratio is 34.87 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co stock appears to be overvalued.
The current stock price of ¥21.13 is trading 41.2% above its estimated GF Value™ of ¥14.96.
GuruFocus considers Hangzhou TianMuShan Pharmaceutical Enterprise Co to be Significantly Overvalued.
Key valuation signals for SHSE:600671:
PB Ratio: 34.87 (14% above median its 10-year median of 30.65)
GF Value™: ¥14.96 vs. price of ¥21.13 (41.2% above fair value)
Industry Position: 1725.7% above the Drug Manufacturers median (#908 of 925)
No single metric tells the full story. See the SHSE:600671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Business Description
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is engaged in producing proprietary Chinese medicines, biopharmaceuticals, healthy foods, medical equipment, and other medicines in China.
54GF Score
Get the complete analysis for SHSE:600671
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600671 has been successfully added to your 
